Merck & Co., Inc. - Net Worth and Insider Trading
Merck & Co., Inc. Net Worth
The estimated net worth of Merck & Co., Inc. is at least $25 Million dollars as of 2024-12-27. Merck & Co., Inc. is the 10% Owner of NGM Biopharmaceuticals Inc and owns about 12,955,016 shares of NGM Biopharmaceuticals Inc (NGM) stock worth over $20 Million. Merck & Co., Inc. is the 10% Owner of Sutro Biopharma Inc and owns about 2,723,509 shares of Sutro Biopharma Inc (STRO) stock worth over $5 Million. Merck & Co., Inc. is also the 10% Owner of Harpoon Therapeutics Inc and owns about 1,000 shares of Harpoon Therapeutics Inc (HARP) stock worth over $23,010. Details can be seen in Merck & Co., Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Merck & Co., Inc. has not made any transactions after 2024-03-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Merck & Co., Inc.
Merck & Co., Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Merck & Co., Inc. owns 7 companies in total, including Arqule Inc (ARQL) , NGM Biopharmaceuticals Inc (NGM) , and Sutro Biopharma Inc (STRO) among others .
Click here to see the complete history of Merck & Co., Inc.’s form 4 insider trades.
Insider Ownership Summary of Merck & Co., Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARQL | Arqule Inc | 2019-12-06 | 10 percent owner |
| NGM | NGM Biopharmaceuticals Inc | 2019-04-08 | 10 percent owner |
| STRO | Sutro Biopharma Inc | 2018-10-01 | 10 percent owner |
 | | 2018-01-24 | 10 percent owner |
| | 2015-07-14 | 10 percent owner |
| | 2016-02-02 | 10 percent owner |
| | 2021-05-07 | 10 percent owner |
Merck & Co., Inc. Latest Holdings Summary
Merck & Co., Inc. currently owns a total of 3 stocks. Among these stocks, Merck & Co., Inc. owns 12,955,016 shares of NGM Biopharmaceuticals Inc (NGM) as of April 8, 2019, with a value of $20 Million and a weighting of 78.74%. Merck & Co., Inc. owns 2,723,509 shares of Sutro Biopharma Inc (STRO) as of October 1, 2018, with a value of $5 Million and a weighting of 21.17%. Merck & Co., Inc. also owns 1,000 shares of Harpoon Therapeutics Inc (HARP) as of March 11, 2024, with a value of $23,010 and a weighting of 0.09%.
Latest Holdings of Merck & Co., Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NGM | NGM Biopharmaceuticals Inc | 2019-04-08 | 12,955,016 | 1.54 | 19,950,725 |
| STRO | Sutro Biopharma Inc | 2018-10-01 | 2,723,509 | 1.97 | 5,365,313 |
| HARP | Harpoon Therapeutics Inc | 2024-03-11 | 1,000 | 23.01 | 23,010 |
Holding Weightings of Merck & Co., Inc.
Merck & Co., Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 0 transactions in NGM Biopharmaceuticals Inc (NGM) over the past 5 years. The most-recent trade in NGM Biopharmaceuticals Inc is the acquisition of 4,121,683 shares on April 8, 2019, which cost Merck & Co., Inc. around $66 Million.
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 0 transactions in Sutro Biopharma Inc (STRO) over the past 5 years. The most-recent trade in Sutro Biopharma Inc is the acquisition of 666,666 shares on October 1, 2018, which cost Merck & Co., Inc. around $10 Million.
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 1 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Harpoon Therapeutics Inc is the acquisition of 21,397,205 shares on March 11, 2024, which cost Merck & Co., Inc. around $492 Million.
Insider Trading History of Merck & Co., Inc.
- 1
Merck & Co., Inc. Trading Performance
GuruFocus tracks the stock performance after each of Merck & Co., Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Merck & Co., Inc. is -26.09%. GuruFocus also compares Merck & Co., Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Merck & Co., Inc. within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Merck & Co., Inc.'s insider trading performs compared to the benchmark.
Performance of Merck & Co., Inc.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -13.55 | | | | | |
| Relative Return to S&P 500(%) | -10.12 | | | | | |
Merck & Co., Inc. Ownership Network
Merck & Co., Inc. Owned Company Details
What does Arqule Inc do?
Who are the key executives at Arqule Inc?
Merck & Co., Inc. is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include director & Chief Executive Officer Paolo Pucci , CFO and Treasurer Marc Schegerin , and See Remarks Brian Schwartz .
Arqule Inc (ARQL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arqule Inc Insider Transactions
Merck & Co., Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Merck & Co., Inc.. You might contact Merck & Co., Inc. via mailing address: 2000 Galloping Hill Road, Kenilworth Nj 07033.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
